Stryker's Growth Improves but Execution Risks Persist

Earnings

โดย Zacks Investment Research·

Summary · why it matters

Stryker Corporation delivered 9% organic sales growth in the second quarter of 2026, with adjusted earnings up 17.9% to $3.69 per share and adjusted operating margin rising 170 basis points to 27.4%. MedSurg and Neurotechnology grew 9.2% organically while Orthopaedics increased 8.6%, and management narrowed its full-year organic sales growth outlook to 8.3% to 9.3%. The stock trades at 20.4 times forward earnings, below its five-year median of 26.0 times but above the Zacks sub-industry average of 16.9 times. Stryker ended the quarter with about $3.5 billion in cash and marketable securities, operating cash flow of $1.8 billion in the first half, and long-term debt down to $14.2 billion from $14.9 billion at year-end 2025. The company plans to resume share repurchases in the second half, while cyber remediation costs, vascular supply constraints, and acquisition integration keep execution risk elevated.

Stryker Corporation ▲